$CDNA
CareDx, Inc. Stock $cdna

$cdna Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000121723422000056 Filed on February 24, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$79.22M	$296.4M	$58.64M
YoY Change	35.1%	54.22%	63.7%
Cost Of Revenue	$27.00M	$97.39M	$18.89M
YoY Change	42.94%	54.34%	48.51%
Gross Profit	$52.22M	$199.0M	$39.76M
YoY Change	31.34%	54.15%	72.05%
Gross Profit Margin	65.92%	67.14%	67.8%
Selling, General & Admin	$44.97M	$152.2M	$29.50M
YoY Change	52.45%	48.26%	49.75%
% of Gross Profit	86.12%	76.48%	74.2%
Research & Development	$22.05M	$76.53M	$13.33M
YoY Change	65.39%	56.36%	48.94%
% of Gross Profit	42.22%	38.45%	33.53%
Depreciation & Amortization	$2.496M	$2.700M	$1.960M
YoY Change	27.35%	42.11%	16.67%
% of Gross Profit	4.78%	1.36%	4.93%
Operating Expenses	$67.62M	$326.1M	$42.82M
YoY Change	57.91%	51.88%	49.46%
Operating Profit	-$15.40M	-$29.73M	-$3.060M
YoY Change	403.24%	31.95%	-44.77%
Interest Expense	$69.00K	$160.0K	-$380.0K
YoY Change	-118.16%	-40.96%	-159.38%
% of Operating Profit
Other Income/Expense, Net	-$1.722M	-$2.362M	-$240.0K
YoY Change	617.5%	-185.03%	200.0%
Pretax Income	-$17.05M	-$32.09M	-$3.690M
YoY Change	362.11%	62.47%	-25.9%
Income Tax	-$901.0K	-$1.426M	-$170.0K
% Of Pretax Income
Net Earnings	-$16.15M	-$30.66M	-$3.520M
YoY Change	358.84%	63.85%	-26.31%
Net Earnings / Revenue	-20.39%	-10.34%	-6.0%
Basic Earnings Per Share		-$0.59
Diluted Earnings Per Share	-$305.5K	-$0.59	-$71.33K
COMMON SHARES
Basic Shares Outstanding	52.80M shares	52.24M shares	49.26M shares
Diluted Shares Outstanding		52.24M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$348.5M	$348.5M	$224.7M
YoY Change	55.09%	55.09%	488.22%
Cash & Equivalents	$348.5M	$348.5M	$134.7M
Short-Term Investments	$0.00	$0.00	$90.00M
Other Short-Term Assets	$7.928M	$7.928M	$3.800M
YoY Change	108.63%	108.63%	5.56%
Inventory	$17.19M	$17.19M	$10.01M
Prepaid Expenses
Receivables	$59.76M	$59.76M	$34.62M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$433.4M	$433.4M	$273.1M
YoY Change	58.68%	58.68%	279.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.04M	$40.04M	$10.70M
YoY Change	105.94%	54.58%	141.63%
Goodwill	$37.00M		$23.86M
YoY Change	55.09%		0.0%
Intangibles	$50.20M		$44.36M
YoY Change	13.17%		-2.6%
Long-Term Investments
YoY Change
Other Assets	$5.835M	$6.046M	$1.000M
YoY Change	483.5%	365.08%	0.0%
Total Long-Term Assets	$133.3M	$133.3M	$95.41M
YoY Change	39.67%	39.69%	19.55%
TOTAL ASSETS
Total Short-Term Assets	$433.4M	$433.4M	$273.1M
Total Long-Term Assets	$133.3M	$133.3M	$95.41M
Total Assets	$566.6M	$566.6M	$368.5M
YoY Change	53.76%	53.76%	142.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.34M	$13.34M	$9.653M
YoY Change	38.16%	37.49%	75.32%
Accrued Expenses	$43.79M	$43.79M	$25.60M
YoY Change	71.06%	71.06%	36.17%
Deferred Revenue	$4.208M		$3.530M
YoY Change	19.21%		-4.23%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$77.30M	$77.30M	$69.22M
YoY Change	11.68%	11.71%	98.74%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$455.0K	$23.03M	$240.0K
YoY Change	89.58%	13.44%	-86.29%
Total Long-Term Liabilities	$455.0K	$23.03M	$240.0K
YoY Change	89.58%	13.44%	-86.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$77.30M	$77.30M	$69.22M
Total Long-Term Liabilities	$455.0K	$23.03M	$240.0K
Total Liabilities	$100.7M	$100.7M	$90.83M
YoY Change	10.91%	10.95%	72.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$383.2M		-$352.5M
YoY Change	8.7%		5.61%
Common Stock	$853.7M		$632.3M
YoY Change	35.02%		44.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$465.9M	$465.9M	$277.7M
YoY Change
Total Liabilities & Shareholders Equity	$566.6M	$566.6M	$368.5M
YoY Change	53.76%	53.76%	142.86%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$16.15M	-$30.66M	-$3.520M
YoY Change	358.84%	63.85%	-26.31%
Depreciation, Depletion And Amortization	$2.496M	$2.700M	$1.960M
YoY Change	27.35%	42.11%	16.67%
Cash From Operating Activities	$4.166M	-$19.29M	$7.180M
YoY Change	-41.98%	-157.71%	-764.81%
INVESTING ACTIVITIES
Capital Expenditures	-$5.848M	-$20.26M	-$440.0K
YoY Change	1229.09%	95.55%	-64.23%
Acquisitions		$15.43M
YoY Change
Other Investing Activities	-$1.934M	$67.97M	-$90.03M
YoY Change	-97.85%	-175.5%	81745.45%
Cash From Investing Activities	-$7.782M	$47.71M	-$90.47M
YoY Change	-91.4%	-147.52%	6651.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-834.0K	$185.6M	3.960M
YoY Change	-121.06%	13.79%	4850.0%
NET CHANGE
Cash From Operating Activities	4.166M	-$19.29M	7.180M
Cash From Investing Activities	-7.782M	$47.71M	-90.47M
Cash From Financing Activities	-834.0K	$185.6M	3.960M
Net Change In Cash	-4.450M	$213.8M	-79.33M
YoY Change	-94.39%	121.6%	3290.17%
FREE CASH FLOW
Cash From Operating Activities	$4.166M	-$19.29M	$7.180M
Capital Expenditures	-$5.848M	-$20.26M	-$440.0K
Free Cash Flow	$10.01M	$965.0K	$7.620M
YoY Change	31.42%	-97.8%	4980.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001217234
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P8Y2M
CY2021	us-gaap	Defined Benefit Plan Type Extensible List DefinedBenefitPlanTypeExtensibleList	http://fasb.org/us-gaap/2021-01-31#PostemploymentRetirementBenefitsMember
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Entity Registrant Name EntityRegistrantName	CAREDX, INC.
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36536
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3316839
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Tower Place
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2021	dei	City Area Code CityAreaCode	415
CY2021	dei	Local Phone Number LocalPhoneNumber	287-2300
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	CDNA
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	4600000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53025142	shares
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	San Jose, California
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	San Jose, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	348485000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134669000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	90034000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59761000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34624000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	17186000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	10012000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7928000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3758000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	433360000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	273097000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	22044000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10704000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17993000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15228000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50195000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44355000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	36983000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	23857000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	211000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	270000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5835000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000000	USD
CY2021Q4	us-gaap	Assets Assets	566621000	USD
CY2020Q4	us-gaap	Assets Assets	368511000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13337000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9653000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	26042000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18466000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	37922000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	20602000	USD
CY2021Q4	cdna	Contract With Customer Liability Current Advance Payment Cares Act ContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct	0	USD
CY2020Q4	cdna	Contract With Customer Liability Current Advance Payment Cares Act ContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct	20496000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	77301000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	69217000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	415000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1299000	USD
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	139000	USD
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	447000	USD
CY2021Q4	cdna	Deferred Payments For Intangible Assets Noncurrent DeferredPaymentsForIntangibleAssetsNoncurrent	5041000	USD
CY2020Q4	cdna	Deferred Payments For Intangible Assets Noncurrent DeferredPaymentsForIntangibleAssetsNoncurrent	3560000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17394000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16069000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	455000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	240000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	100745000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	90832000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52923360	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52923360	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49441166	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49441166	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	52000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	853683000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	632253000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4670000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2096000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-383189000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-352527000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	465876000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	277679000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	566621000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	368511000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	296397000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	192194000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	127068000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	76525000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48941000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30711000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	77245000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	53858000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	38894000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	74964000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48806000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36540000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	326123000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	214722000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	151600000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-29726000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-22528000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-24532000	USD
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	160000	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	271000	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	985000	USD
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	106000	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1495000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	319000	USD
CY2021	cdna	Relief Fund Provider Cares Act ReliefFundProviderCARESAct	0	USD
CY2020	cdna	Relief Fund Provider Cares Act ReliefFundProviderCARESAct	4813000	USD
CY2019	cdna	Relief Fund Provider Cares Act ReliefFundProviderCARESAct	0	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2628000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-811000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-719000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2362000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2778000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	585000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32088000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19750000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23947000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1426000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1036000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1979000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-30662000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-18714000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-21968000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52241076	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46481772	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42151617	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52241076	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46481772	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42151617	shares
CY2021	us-gaap	Profit Loss ProfitLoss	-30662000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-18714000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-21968000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2574000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3109000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-927000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-33236000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-15605000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-22895000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	95928000	USD
CY2019	cdna	Adjustments To Additional Paid In Capital Contingent Consideration Classified As Equity AdjustmentsToAdditionalPaidInCapitalContingentConsiderationClassifiedAsEquity	222000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	759000	USD
CY2019	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-4152000	USD
CY2019	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	209000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3553000	USD
CY2019	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	3181000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22195000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-927000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-21968000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	99000000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1393000	USD
CY2020	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-4529000	USD
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	315000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8007000	USD
CY2020	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	8008000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23055000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3109000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-18714000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	277679000	USD
CY2021	cdna	Adjustments To Additional Paid In Capital Contingent Consideration Classified As Equity AdjustmentsToAdditionalPaidInCapitalContingentConsiderationClassifiedAsEquity	-222000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2139000	USD
CY2021	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-18441000	USD
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	296000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12776000	USD
CY2021	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	205000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35825000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2574000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-30662000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	465876000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-30662000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-18714000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-21968000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	36081000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	23401000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	22417000	USD
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2437000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	160000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8797000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7006000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5523000	USD
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3088000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2538000	USD
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1621000	USD
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1743000	USD
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
CY2019	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-106000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1495000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-319000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-609000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	309000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	210000	USD
CY2021	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	1129000	USD
CY2020	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	0	USD
CY2019	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	0	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	222000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	24416000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10402000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12675000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6927000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3196000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1270000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	5144000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	41000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	829000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1789000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	4389000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1351000	USD
CY2021	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	7516000	USD
CY2020	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	5737000	USD
CY2019	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	3115000	USD
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	10690000	USD
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2911000	USD
CY2019	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	3029000	USD
CY2021	cdna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2603000	USD
CY2020	cdna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1475000	USD
CY2019	cdna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1854000	USD
CY2021	cdna	Increase Decrease In Contract With Customer Liability Current Advance Payment Cares Act IncreaseDecreaseInContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct	20496000	USD
CY2020	cdna	Increase Decrease In Contract With Customer Liability Current Advance Payment Cares Act IncreaseDecreaseInContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct	-20496000	USD
CY2019	cdna	Increase Decrease In Contract With Customer Liability Current Advance Payment Cares Act IncreaseDecreaseInContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct	0	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1379000	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1023000	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1280000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19294000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	33431000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2769000	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	88905000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5500000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	90034000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2021	cdna	Payments To Acquire Capital Expenditures Net PaymentsToAcquireCapitalExpendituresNet	13559000	USD
CY2020	cdna	Payments To Acquire Capital Expenditures Net PaymentsToAcquireCapitalExpendituresNet	7110000	USD
CY2019	cdna	Payments To Acquire Capital Expenditures Net PaymentsToAcquireCapitalExpendituresNet	2201000	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6700000	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3250000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1148000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	15434000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	18230000	USD
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2019	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	47712000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-100394000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22579000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	66000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	183000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	172000	USD
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	225000	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	352000	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	105000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12775000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8006000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3553000	USD
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2139000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1368000	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	760000	USD
CY2021	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	18065000	USD
CY2020	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	4529000	USD
CY2019	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	4153000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	185642000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	163149000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-132000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-303000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	274000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-849000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	213757000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	96460000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26329000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134939000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38479000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64808000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	348696000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134939000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38479000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	10000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	22000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	80000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2021	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	296000	USD
CY2020	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	315000	USD
CY2019	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	209000	USD
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	7207000	USD
CY2021	cdna	Operating Leases Right Of Use Assets Of Cash Flow Information OperatingLeasesRightOfUseAssetsOfCashFlowInformation	6079000	USD
CY2020	cdna	Operating Leases Right Of Use Assets Of Cash Flow Information OperatingLeasesRightOfUseAssetsOfCashFlowInformation	55000	USD
CY2019	cdna	Operating Leases Right Of Use Assets Of Cash Flow Information OperatingLeasesRightOfUseAssetsOfCashFlowInformation	6138000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3953000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	274000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	576000	USD
CY2021	cdna	Employee Stock Purchase Plan Shares EmployeeStockPurchasePlanShares	1521000	USD
CY2020	cdna	Employee Stock Purchase Plan Shares EmployeeStockPurchasePlanShares	800000	USD
CY2019	cdna	Employee Stock Purchase Plan Shares EmployeeStockPurchasePlanShares	703000	USD
CY2021	cdna	Common Stock Shares Issued For Contingent Consideration CommonStockSharesIssuedForContingentConsideration	5341000	USD
CY2020	cdna	Common Stock Shares Issued For Contingent Consideration CommonStockSharesIssuedForContingentConsideration	0	USD
CY2019	cdna	Common Stock Shares Issued For Contingent Consideration CommonStockSharesIssuedForContingentConsideration	1442000	USD
CY2018Q1	cdna	Number Of Renal Transplant Patients NumberOfRenalTransplantPatients	1700	patient
CY2021Q4	cdna	Number Of Transplant And Nephrology Centers Offering Remo Tra C NumberOfTransplantAndNephrologyCentersOfferingRemoTraC	200	center
CY2021Q4	cdna	Number Of Patients Enrolled In Remo Tra C NumberOfPatientsEnrolledInRemoTraC	11000	patient
CY2021Q4	cdna	Number Of Mobile Phlebotomists NumberOfMobilePhlebotomists	10000	phlebotomist
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-383200000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	348500000	USD
CY2020Q2	cdna	Cares Act Centers For Medicare And Medicaid Services Proceeds From Advance Payment CARESActCentersForMedicareAndMedicaidServicesProceedsFromAdvancePayment	20500000	USD
CY2021Q4	us-gaap	Grants Receivable GrantsReceivable	30000000000	USD
CY2021Q4	us-gaap	Grants Receivable GrantsReceivable	30000000000	USD
CY2020Q2	cdna	Proceeds From Grants ProceedsFromGrants	4800000	USD
CY2020Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	134600000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing revenue; standalone fair value of patient and digital solutions revenue performance obligations; accrued expenses for clinical studies; inventory valuation; the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired); the fair value of contingent consideration recorded in connection with a business combination or an asset acquisition; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, corporate debt securities and various bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets that may be in excess of insured limits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to credit risk from its accounts receivable, which are derived from revenue earned from AlloSure Kidney, AlloSure Heart and AlloMap Heart tests provided for patients located in the U.S. and Canada, and billed to various third-party payers, from sales of products to distributors, strategic partners and transplant laboratories in Europe, Asia, the Middle East, Africa, the U.S., Latin America and other geographic regions, from sales of patient and digital solutions software. The Company has not experienced any significant credit losses and does not require collateral on receivables. For the years ended December 31, 2021, 2020 and 2019, approximately 59%, 57% and 55%, respectively, of total revenue was billed to Medicare. No other payers represented more than 10% of total revenue for the years ended December 31, 2021, 2020 and 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, approximately 27% and 28%, respectively, of accounts receivable was due from Medicare. No other payer represented more than 10% of accounts receivable at either December 31, 2021 or 2020.</span></div>
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	200000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-30662000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-18714000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-21968000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-30662000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-18714000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21968000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52241076	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46481772	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42151617	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52241076	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46481772	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42151617	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3914422	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4555528	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4481383	shares
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	6607000	USD
CY2020	cdna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Exercise Of Warrants FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisExerciseOfWarrants	7655000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1495000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	447000	USD
CY2021	cdna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Exercise Of Warrants FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisExerciseOfWarrants	202000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-106000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	5341000	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	5480000	USD
CY2021Q4	cdna	Number Of Investments NumberOfInvestments	1	investment
CY2021	cdna	Business Combination Contingent Consideration Liability Measurement Input Discount Rate BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate	0.12
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	348485000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134669000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38223000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	211000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	270000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	256000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	348696000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134939000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38479000	USD
CY2021Q4	cdna	Marketable Securities Amortized Cost Long Term MarketableSecuritiesAmortizedCostLongTerm	5500000	USD
CY2021Q4	cdna	Marketable Securities Accumulated Unrecognized Holding Gain Loss Long Term MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm	-1743000	USD
CY2021Q4	cdna	Marketable Securities Fair Value Long Term MarketableSecuritiesFairValueLongTerm	3757000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Amortized Cost Before Other Than Temporary Impairment HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment	90034000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	136000	USD
CY2020Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	89898000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	0	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	500000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	500000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	23857000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	23857000	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	13126000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2021Q4	us-gaap	Goodwill Goodwill	36983000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	23857000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	73141000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21318000	USD
CY2021Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	2878000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	48945000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	74391000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21318000	USD
CY2021Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	2878000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50195000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	59816000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15518000	USD
CY2020Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	1193000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	43105000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	61066000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15518000	USD
CY2020Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	1193000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3600000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44355000	USD
CY2021	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	13400000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5800000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4800000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	6377000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	6304000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	6068000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	5898000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4822000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	19476000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	48945000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3911000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1702000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2828000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2936000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10447000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5374000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	17186000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	10012000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	41625000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	27703000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10704000	USD
CY2021	us-gaap	Depreciation Depreciation	2700000	USD
CY2020	us-gaap	Depreciation Depreciation	1900000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	19581000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	16999000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	22044000	USD
CY2019	us-gaap	Depreciation Depreciation	1600000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	0	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	600000	USD
CY2021Q4	cdna	Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization FinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	500000	USD
CY2020Q4	cdna	Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization FinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	400000	USD
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	100000	USD
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	100000	USD
CY2019	us-gaap	Adjustment For Amortization AdjustmentForAmortization	200000	USD
CY2021Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	10653000	USD
CY2020Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	6733000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5780000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1529000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4208000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3530000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3958000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2033000	USD
CY2021Q4	cdna	Accrued Capital Expenditures AccruedCapitalExpenditures	2612000	USD
CY2020Q4	cdna	Accrued Capital Expenditures AccruedCapitalExpenditures	0	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2114000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	738000	USD
CY2021Q4	cdna	Deferred Payments For Intangible Assets DeferredPaymentsForIntangibleAssets	2000000	USD
CY2020Q4	cdna	Deferred Payments For Intangible Assets DeferredPaymentsForIntangibleAssets	2000000	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1664000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1072000	USD
CY2021Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	1197000	USD
CY2020Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	416000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3736000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2551000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	37922000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	20602000	USD
CY2020Q2	cdna	Cares Act Centers For Medicare And Medicaid Services Proceeds From Advance Payment CARESActCentersForMedicareAndMedicaidServicesProceedsFromAdvancePayment	20500000	USD
CY2020Q1	cdna	Operating Lease Right Of Use Asset Increase OperatingLeaseRightOfUseAssetIncrease	13000000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18000000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4000000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17400000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5134000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	4441000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1993000	USD
CY2021	cdna	Finance Lease Cost FinanceLeaseCost	53000	USD
CY2020	cdna	Finance Lease Cost FinanceLeaseCost	205000	USD
CY2019	cdna	Finance Lease Cost FinanceLeaseCost	218000	USD
CY2021	us-gaap	Lease Cost LeaseCost	5187000	USD
CY2020	us-gaap	Lease Cost LeaseCost	4646000	USD
CY2019	us-gaap	Lease Cost LeaseCost	2211000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y11M26D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5662000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4332000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7140000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	28737000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4340000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4067000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3196000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7385000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21352000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3958000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17394000	USD
CY2014Q2	cdna	Number Of Milestone Payments NumberOfMilestonePayments	6	milestonePayment
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4200000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	200000	USD
CY2020Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	134600000	USD
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1400000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	USD
CY2021	cdna	Purchase Of Common Stock Warrants Exercised PurchaseOfCommonStockWarrantsExercised	3000	shares
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4000	USD
CY2020	cdna	Purchase Of Common Stock Warrants Exercised PurchaseOfCommonStockWarrantsExercised	314000	shares
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	400000	USD
CY2020	cdna	Number Of Warrants Exercised Cashless Basis NumberOfWarrantsExercisedCashlessBasis	34000	shares
CY2020	cdna	Stock Issued During Period Shares Cashless Warrants Exercises In Period StockIssuedDuringPeriodSharesCashlessWarrantsExercisesInPeriod	24000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	672968	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2670398	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.92
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1977647	shares
CY2021	cdna	Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices	3984	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1159947	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	202514	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	202514	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	79.35
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	753383	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	17.10
CY2021	cdna	Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans	237774	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	288689	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	245253	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	245253	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	27.93
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	10643	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	10643	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	25.71
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2066529	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1863633	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.33
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	42900000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	19200000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	15100000	USD
CY2021Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	956596	shares
CY2021	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	20.30
CY2021	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P6Y7M6D
CY2021Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue	24396000	USD
CY2021Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	830469	shares
CY2021Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	38.97
CY2021	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P8Y2M8D
CY2021Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	11545000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1787065	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	35941000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	52.65
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.97
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.74
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	11700000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	19500000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M12D
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36081000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23401000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22417000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-27921000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-14233000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-19386000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4167000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5517000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4561000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32088000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19750000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23947000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	89000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-58000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-571000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-139000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	160000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	83000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-48000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	103000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-487000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-409000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	91000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-558000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-127000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-52000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-47000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-842000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1178000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-887000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1378000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1139000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1492000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1426000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1036000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1979000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.388
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.135
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.099
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.864
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.344
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.166
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.007
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.018
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003
CY2021	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	0
CY2020	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	-0.017
CY2019	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	0.003
CY2021	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	0
CY2020	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	-0.003
CY2019	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	-0.002
CY2021	cdna	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Share Based Compensation Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveShareBasedCompensationCostPercent	-0.234
CY2020	cdna	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Share Based Compensation Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveShareBasedCompensationCostPercent	-0.068
CY2019	cdna	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Share Based Compensation Cost Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveShareBasedCompensationCostPercent	-0.076
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.069
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.039
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.026
CY2021	cdna	Effective Income Tax Rate Reconciliation Changes In Net Operating Loss Carryforwards Percent EffectiveIncomeTaxRateReconciliationChangesInNetOperatingLossCarryforwardsPercent	-1.251
CY2020	cdna	Effective Income Tax Rate Reconciliation Changes In Net Operating Loss Carryforwards Percent EffectiveIncomeTaxRateReconciliationChangesInNetOperatingLossCarryforwardsPercent	0.069
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	4598000	USD
CY2019	cdna	Effective Income Tax Rate Reconciliation Changes In Net Operating Loss Carryforwards Percent EffectiveIncomeTaxRateReconciliationChangesInNetOperatingLossCarryforwardsPercent	-0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.009
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.012
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.044
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.052
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.083
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30234000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	60578000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7185000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	8507000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	6054000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1043000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1047000	USD
CY2021Q4	cdna	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	4639000	USD
CY2020Q4	cdna	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	4408000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7988000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4302000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57143000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	83440000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45635000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	72860000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11508000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10580000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	7439000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	7683000	USD
CY2021Q4	cdna	Deferred Tax Liabilities Operating Leases Right Of Use Assets DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets	3828000	USD
CY2020Q4	cdna	Deferred Tax Liabilities Operating Leases Right Of Use Assets DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets	3708000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	656000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	488000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11923000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11879000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	415000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1299000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-27200000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8400000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-27200000	USD
CY2021Q4	cdna	Research And Development Credits Expected To Be Limited ResearchAndDevelopmentCreditsExpectedToBeLimited	3900000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4416000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3650000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3449000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	805000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1195000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	58000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	466000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	824000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	667000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	130000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4156000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4416000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3650000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4200000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	200000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	296397000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	192194000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10704000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	127068000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22044000	USD

Files In Submission

Name	View Source	Status
0001217234-22-000056-index-headers.html	Edgar Link	pending
0001217234-22-000056-index.html	Edgar Link	pending
0001217234-22-000056.txt	Edgar Link	pending
0001217234-22-000056-xbrl.zip	Edgar Link	pending
caredx-form10xkex48descrip.htm	Edgar Link	pending
cdna-20211231.htm	Edgar Link	pending
cdna-20211231.xsd	Edgar Link	pending
cdna-20211231x10kxexx311.htm	Edgar Link	pending
cdna-20211231x10kxexx312.htm	Edgar Link	pending
cdna-20211231x10kxexx321.htm	Edgar Link	pending
cdna-20211231_cal.xml	Edgar Link	unprocessable
cdna-20211231_def.xml	Edgar Link	unprocessable
cdna-20211231_g1.jpg	Edgar Link	pending
cdna-20211231_htm.xml	Edgar Link	completed
cdna-20211231_lab.xml	Edgar Link	unprocessable
cdna-20211231_pre.xml	Edgar Link	unprocessable
exhibit211-listofsubs2021.htm	Edgar Link	pending
exhibit231-deloitteconsent.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDNA
CareDx, Inc. Stock $cdna

2021 Q4 Form 10-K Financial Statement

#000121723422000056 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA CareDx, Inc. Stock $cdna

2021 Q4 Form 10-K Financial Statement

#000121723422000056 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA
CareDx, Inc. Stock $cdna